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Abstract
Anemia aﬀects over 800 million women and children globally. Measurement of hepcidin as an
index of iron status shows promise, but its diagnostic performance where hemoglobinopathies are
prevalent is unclear. We evaluated the performance of hepcidin as a diagnostic test of iron deﬁ-
ciency in adolescents across Sri Lanka.
We selected 2273 samples from a nationally representative cross-sectional study of 7526 sec-
ondary schoolchildren across Sri Lanka and analyzed associations between hepcidin and
participant characteristics, iron indices, inﬂammatory markers, and hemoglobinopathy states. We
evaluated the diagnostic accuracy of hepcidin as a test for iron deﬁciency with estimation of the
AUCROC, sensitivity/speciﬁcity at each hepcidin cutoﬀ, and calculation of the Youden Index to ﬁnd
the optimal threshold.
Hepcidin was associated with ferritin, sTfR, and hemoglobin. The AUCROC for hepcidin as a test
of iron deﬁciency was 0.78; hepcidin outperformed Hb and sTfR. The Youden index-predicted cut-
oﬀ to detect iron deﬁciency (3.2 ng/mL) was similar to thresholds previously identiﬁed to predict
iron utilization and identify deﬁciency in African populations. Neither age, sex, nor a- or
b-thalassemia trait aﬀected diagnostic properties of hepcidin. Hepcidin pre-screening would pre-
vent most iron-replete thalassemia carriers from receiving iron whilst still ensuring most iron
deﬁcient children were supplemented. Our data indicate that the physiological relationship
between hepcidin and iron status transcends speciﬁc populations. Measurement of hepcidin in
individuals or populations could establish the need for iron interventions.
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1 | INTRODUCTION
About 800 million women and children are anemic worldwide, with the
prevalence highest in Asia and sub-Saharan Africa.1 Reducing the burden
of anemia is a core 2025 global nutrition target. These goals form the
basis for the rationale for programmes aimed at improving iron stores
where the burden of anemia is high. For example, India, where the
prevalence of anemia in adolescents is 56–90%,2 oﬀers weekly iron
supplementation to over 100 million adolescent boys and girls.3
Elsewhere, anemia may be less prevalent, and importantly, may be
attributable to causes other than iron deﬁciency. For example, in Cam-
bodia only a minority of anemia in schoolchildren is attributable to
iron deﬁciency, with hemoglobinopathy being the dominant cause.4 In
Sri Lanka, the prevalence of anemia in adolescents is about 20%2; and
hence this group may be a candidate for long term weekly iron sup-
plementation. However, Sri Lanka also has a high concomitant burden
of genetic hemoglobinopathy, including carriage of a-globin deletions
(especially a-3.7), and ß-globin mutations (ß-thalassemia and Hemoglo-
bin-E).5 Importantly, there are established concerns regarding safety of
universal iron programs due to risks of malaria6 and alterations in
intestinal microbiota,7 and emerging concerns about risk of iron over-
load especially in populations at high risk of hemoglobinopathy. In set-
tings such as Sri Lanka, universal iron may only beneﬁt the minority
with iron deﬁciency anemia, provide no beneﬁt, and perhaps harm.
Stratiﬁcation of iron interventions may therefore be of value.
Hepcidin is the peptide hormone that regulates iron homeostasis.8
Plasma hepcidin directly mediates iron absorption and utilization from
the intestine, and is upregulated by iron stores and inﬂammation and
suppressed by iron deﬁciency and increased erythropoiesis.9 Hepcidin
might be marginally suppressed in carriers of thalassemia,10 resulting
in increased iron absorption in this group and perhaps exposing them
to risks of iron overload when subjected to prolonged iron supplemen-
tation.11 Hepcidin has been evaluated as a potential indicator of iron
status and iron absorption,12 and has been shown to select African
children whom might beneﬁt from iron supplementation.13 Hepcidin
could provide a useful tool to direct iron to individuals in settings
where, while anemia still presents an important public health problem,
the prevalence may not warrant universal supplementation, or where
other factors (e.g., thalassemia carriage) contribute greatly to anemia.
In a nationally representative study of Sri Lankan secondary school
children we collected data from a sample enriched for individuals at
risk of iron deﬁciency or thalassemia carriage. We investigated the rela-
tionship between hepcidin and iron status, with interactions for thalas-
semia, then evaluated the properties of hepcidin as a diagnostic test of
iron deﬁciency in this population and identiﬁed the optimal diagnostic
threshold for hepcidin.
2 | SUBJECTS AND METHODS
2.1 | Study design
We obtained samples from a nationally representative cross-sectional
study designed to assess the frequency and distribution of hemoglobin
variants across Sri Lanka. From each of 25 districts we purposefully
selected approximately three schools (72 in total, including 5 temporary
schools for displaced students from the North) that were geographi-
cally spaced and representative of the population.14 Participants were
eligible if they were attending a selected secondary school and were
aged 12–19 years inclusive. Samples were collected between June
2009 and July 2010.
2.2 | Laboratory measurements
We collected a 5 mL blood sample from each student and transferred
it into EDTA and plain tubes. We measured Hb and red cell indices
(Coulter Counter, Beckman Coulter UK) and identiﬁed Hb variants by
High Performance Liquid Chromatography using the ß-thalassemia
short program (BioRad, India). DNA was tested for a-globin gene dele-
tions (3.7 and 4.2) by multiplex PCR.15 We measured serum ferritin
and transferrin receptor (sTfR) by ELISA (IBL International and R&D
systems, respectively), and inﬂammation (hsCRP, Architect C8000,
Abbott Laboratories). The sTfR-ferritin (sTfR-F) index was calculated as
sTfR/log10(ferritin). Results for diagnostic reference standards were not
viewed by the operator measuring hepcidin.
We quantiﬁed serum hepcidin by competitive ELISA (hepcidin-25
human bioactive ELISA and hepcidin-25 High Sensitivity ELISA, DRG).
The high sensitivity ELISA was introduced by DRG during the course of
the study; we calculated an adjustment factor to ensure comparability
based on data provided by DRG. We validated the adjustment by ensur-
ing mean hepcidin concentrations were not diﬀerent between control
groups assayed using both kits, in which mean ferritin, sTfR, and CRP
were also similar. The lower limit of detection (LOD), estimated as being
the hepcidin value corresponding to 3SDs below the mean 0 ng/mL hep-
cidin standard OD450, was calculated to be 0.78 ng/mL. Samples that
gave readings less than the LOD were reported as LOD/2 (0.39 ng/mL).
Inter-plate coeﬃcients of variation (CV%) for the mean OD450 nm on
the “old” DRG kit: high and low concentration controls (provided by kit)
were 13.8 and 12.2, respectively (n556). Inter-plate CV% for the mean
OD450 nm on the new HS-DRG kit for high and low controls (included
with the assay) were 9.0% and 10.6%, respectively (n59).
Multiple commercial assays are available for hepcidin measure-
ment and, whilst correlation has been shown to be good between
some speciﬁc assays,16 each assay measures diﬀerent absolute values
of hepcidin, thereby preventing direct comparison of results between
measurements obtained using diﬀerent assays. For this reason, twenty-
eight additional samples were also run in parallel using the DRG
hepcidin-25 bioactive ELISA and the Bachem Hepcidin-25 (human)
Enzyme Immunoassay (run as previously described)13 to allow compari-
son of results between methods.
2.3 | Statistics
Data were analyzed using Stata 11 (StataCorp., College Station, TX).
Hepcidin, ferritin, sTfR, CRP, and sTfR-F index data were skewed and
variables were log10 transformed for analysis. Arithmetic or geometric
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means were calculated where appropriate along with the 2.5th to
97.5th centile range.
Using linear regression, we estimated associations between hepci-
din, participant characteristics, inﬂammatory markers and iron indices.
Statistical signiﬁcance was deﬁned as P<0.05 and b coeﬃcients were
estimated by analysis of variables standardized such that their varian-
ces were 1. We performed stepwise multiple regression, and retained
only those variables with P<0.05. Regression diagnostics were per-
formed and the optimal model selected. Missing data were handled by
listwise deletion for particular analyses.
We used a gold standard deﬁnition of iron deﬁciency, termed
“combined deﬁnition”, previously deployed in sub-Saharan African chil-
dren: serum ferritin<15 ng/mL, or <30 ng/mL in the presence of
CRP>5 mg/L, and sTfR/log10ferritin (sTfR-F) index>2.
13 This
FIGURE 1 Flow of participants through the study
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deﬁnition combines the current WHO deﬁnition of iron deﬁciency using
ferritin (adjusted for inﬂammation),17 along with cutoﬀs of the sTfR-F
index.18 This “combined deﬁnition” ensures that individuals with ferritin
concentrations between 15 and 30 ng/mL and inﬂammation are only con-
sidered iron deﬁcient if they also demonstrate tissue iron depletion.13 In
order to permit comparison of sTfR with hepcidin, we used a second gold
standard: “ferritin alone,” reﬂecting current WHO guidelines: ferritin<15
or<30 ng/mL in the presence of inﬂammation (CRP>5 mg/L).17
Receiver operating characteristic (ROC) curves were graphed and
area under the curve (AUCROC) values calculated. We compared the
AUCROC of hepcidin to detect iron deﬁciency between individuals
with/without carriage of hemoglobinopathy. Sensitivities and speciﬁc-
ities were calculated for each cutoﬀ of hepcidin and the Youden index
[(sensitivity1 speciﬁcity) – 1] estimated. The ROC curves and Youden
index were inspected to determine the point at which the sensitivity
and speciﬁcity were both maximized.
2.4 | ETHICS
Approval for this research program was obtained from the Ethical
Committee of the University of Kelaniya, Colombo, Sri Lanka; and
the Oxford Tropical Research Ethical Committee, Oxford, United
Kingdom. Permission for enrolment into the study was obtained
from each of the schools and families involved.
2.5 | Role of the funding source
The funding source had no role in the collection, analysis, and interpre-
tation of data; in the writing of the report; or in the decision to submit
the paper for publication. The corresponding authors had full access to
all the data in the study and had ﬁnal responsibility for the decision to
submit for publication.
3 | RESULTS
From a total of 7526 students we analyzed samples from 2273 children
aged 12–19 years: 587 with normal red cell indices and 1686 with low
red cell indices (MCV<80 fL and/or MCH<27 pg), enriching our dataset
for hemoglobinopathies. The ﬂow of participants is detailed in Figure 1.
Participant demographics and iron indices are summarized in Table
1. The prevalence of anemia within this selected study group was
19.8%, and using the combined deﬁnition iron deﬁciency was seen in
19.2% and was more prevalent in girls (27.6%) than boys (10.4%)
(P<0.001). Only 3.5% of children had inﬂammation as deﬁned by
CRP>5 ng/mL. Geometric mean hepcidin for the overall group was
3.86 ng/mL [95% conﬁdence interval 1.01–16.39]; in iron replete indi-
viduals it was 4.44 ng/mL [4.30–4.59] compared with 2.27 ng/mL
[2.14–2.40] in iron deﬁcient children (P<0.001) and 2.81 ng/mL
[2.62–3.01] in anemic children.
Of our sample, 5.2% had b-thalassemia trait, 21.6% a1 thalassemia
trait (heterozygous), 0.9% were a1 homozygous or compound hetero-
zygous thalassemia, and 1.2% HbE trait. Hepcidin was suppressed in
non-iron deﬁcient b-thalassemia trait carriers (4.1 ng/mL) compared
with non-iron deﬁcient children without hemoglobinopathy (5.2 ng/mL,
P<0.001) (Supporting Information Table I). This eﬀect was also seen in
the non-iron deﬁcient a-thalassemia carriers compared to the non-iron
deﬁcient samples without hemoglobinopathy (4.8 ng/mL vs 5.3 ng/mL,
P50.02) (Supporting Information Figure 1).
3.1 | Associations with hepcidin
We evaluated associations of hepcidin with demographic characteristics
and erythropoietic, iron, and inﬂammatory indices (Table 2). By univariate
linear regression, hepcidin was associated with age, sex, Hb, ferritin,
CRP, sTfR, and sTfR-F index. By stepwise multiple regression analysis,
hepcidin was associated with ferritin, sTfR, Hb, and CRP with an adjusted
R250.259 (Table 2). Hepcidin was not associated with age, sex or car-
riage of hemoglobinopathy after adjustment, indicating that these factors
mediate their eﬀect on hepcidin via iron stores and erythropoiesis.
3.2 | Hepcidin as a diagnostic test of iron deﬁciency
We generated ROC curves and measured the AUCROC for hepcidin as
a test for iron deﬁciency with the combined deﬁnition (Figure 2A). The
AUCROC was 0.78 [0.76–0.81]. We next compared the performance of
TABLE 1 Summary of patient characteristics and iron indices
Variable
Age, Mean [2.5, 97.5 centile] (years) 15.9 [14, 19]
Female, n/N (%) 1166/2273 (51.2)
Hemoglobinopathy
b-thalassemia trait, n/N (%) 118/2263 (5.2)
a-thalassemia trait, n/N (%) 474/2198 (21.6)
a-homozygous or compound
heterozygous thalassemia, n/N (%)
20/2198 (0.9)
HbE, n/N (%) 28/2273 (1.2)
Iron parameters
Variable Mean [2.5, 97.5 centile] Abnormal n/N (%)b
Hepcidin (ng/mL) 3.86a [1.01, 16.39]
Ferritin (ng/mL) 24.1a [2.76, 106.57] 585/2210 (26.5)
CRP (mg/L) 0.42a [0.07, 7.12] 74/2117 (3.5)
Hb (g/dL) 13.58 [10.4, 17.1] 439/2217 (19.8)
sTfR (mg/L) 1.99a [1.04, 5.13] 884/2255 (39.4)
sTfR-F index 1.52a [0.63, 6.29] 563/2203 (25.6)
Iron Deﬁciency
(combined deﬁnition),c
n/N (%)
422/2203 (19.2)
aGeometric mean.
bFerritin<15 ng/mL; CRP>5 mg/L; Hb< 12 g/dL in girls and in boys
12–14 years, Hb<13 g/dL in boys 14–19 years; sTfR>2.074 mg/L;
sTfR-F>2.
cFerritin<15 ng/mL, or ferritin<30 ng/mL if CRP>5 mg/L, and sTfR-
F>2.
WRAY ET AL. AJH | 199
hepcidin as a diagnostic test of iron deﬁciency to other indices of iron
status (deﬁned by the “ferritin alone”). Hepcidin (AUCROC 0.75 [0.73–
0.77]) performed signiﬁcantly better than either Hb (AUCROC 0.68 [0.65–
0.70], P<0.001) or sTfR (AUCROC 0.66 [0.64–0.69], P<0.001) (Figure
2B). The diagnostic test accuracy of hepcidin was not diﬀerent when
AUCROC were compared by sex, or anemia or carriage of ß-thalassemia,
a-thalassemia, and HbE (Figure 2C) (Supporting Information Table II).
We next estimated the diagnostic properties of several potential
hepcidin thresholds. Hepcidin<3.2 ng/mL achieved the maximum
Youden index (0.46) (Figure 2D), and correctly classiﬁed 71.3% of sam-
ples, with a sensitivity of 75.6% and a speciﬁcity of 70.2%. Alternative
thresholds could be selected which yielded diﬀerent sensitivity and
speciﬁcity (Supporting Information Table III). At the same hepcidin cut-
oﬀ, 72.1% of the b-thalassemia carriers were correctly classiﬁed, with a
sensitivity of 76.2% and speciﬁcity of 71.3%.
To compare this threshold to previous data, we analyzed the hep-
cidin concentrations of twenty-eight samples using both the DRG and
Bachem assays (Supporting Information Figure 2). Although absolute
hepcidin values diﬀer between the two assays, there was a linear cor-
relation (R250.92) between results returned by the two assays. We
previously identiﬁed an optimal hepcidin threshold, using the Bachem
assay, of 5.5 ng/mL (based on the Youden index) in African pre-school
children.13 This threshold corresponds to a hepcidin value of 3.1 ng/mL
with the DRG assay, which is similar to the cutoﬀ identiﬁed in the Sri
Lankan population.
Finally, we sought to establish the clinical implications if iron treat-
ment was stratiﬁed in this adolescent population using hepcidin, com-
pared with universal distribution of iron or distribution predicated on
detection of anemia (Supporting Information Table IV). Provision of
iron only to individuals with hepcidin<3.2 ng/mL prevented about
60% of total individuals from receiving iron whilst ensuring at least
three quarters of iron deﬁcient individuals received iron. Had screening
been undertaken using testing for anemia, only 36% of iron deﬁcient
individuals would receive iron. Importantly, if Hb screening alone had
been undertaken, directing iron on the basis of anemia would result in
two thirds of iron-replete ß-thalassemia carriers (in whom iron supple-
mentation may result in loading) receiving iron, whereas directing iron
based on hepcidin could reduce this to only 29% of carriers. Likewise,
hepcidin-directed iron interventions would reach 68% of alpha thalas-
semia carriers (compared with 40% based on anemia-screening),
although the number of iron replete alpha thalassemia carriers receiv-
ing iron would be increased (from 13% to 28%).
4 | DISCUSSION
In a large cross-sectional study of adolescents across Sri Lanka, we
assessed regulation of serum hepcidin concentrations and the value of
this biomarker as an index of iron deﬁciency. At the population level,
associations with serum hepcidin concentration represent known regu-
lation of its gene expression by iron, erythropoiesis, and inﬂammation.
TABLE 2 Associations between hepcidin and participant characteristics and iron indices
Variable Regression Coeﬃcient 95% CI P b coeﬃcienta
Univariate linear regression for log10(hepcidin)
Age (years) 0.048 0.025, 0.070 <0.001 0.090
Sexb 20.24 20.30, 20.18 <0.001 20.16
Hb (g/dL) 0.13 0.11, 0.15 <0.001 0.30
log10(ferritin) 0.37 0.34, 0.40 <0.001 0.46
log10(sTfR) 20.50 20.58, 20.43 <0.001 20.27
log10(sTfR-F) 20.52 20.56, 20.47 <0.001 20.43
log10(CRP) 0.15 0.12, 0.18 <0.001 0.23
b-thalassemia trait 20.02 20.16, 0.12 0.76 20.006
HbE trait 0.15 20.12, 0.43 0.27 0.023
a-thalassemia trait 0.12 0.044, 0.19 0.002 0.066
a-homozygous or compound heterozygous thalassemia 0.49 0.16, 0.81 0.003 0.063
Multiple linear regression model for log10(hepcidin)
Log10(ferritin) 0.27 0.24, 0.30 <0.001 0.34
Log10(sTfR) 20.25 20.32, 20.17 <0.001 20.13
Hb (g/dL) 0.05 0.04, 0.07 <0.001 0.13
Log10(CRP) 0.10 0.07, 0.12 <0.001 0.15
All variables were included in the multiple regression analysis. Only variables with P<0.05 were included in the ﬁnal ﬁtted model.
aVariables standardized to have a variance of 1, allowing comparison of regression coeﬃcients between variables.
bCoded variable: Male5 0; Female5 1.
200 | AJH WRAY ET AL.
Performance of hepcidin as an index of iron deﬁciency in this popula-
tion was not perturbed by carriage of thalassemia. Importantly, the
threshold for hepcidin we identiﬁed was similar to previously reported
cutoﬀs identiﬁed in studies in Africa and elsewhere in Asia. This is the
largest diagnostic test accuracy study for hepcidin as a test of iron deﬁ-
ciency, the ﬁrst such study in South Asia, and the ﬁrst in a setting
where hemoglobinopathy is endemic.
Our data conﬁrm at the population level the known mechanistic
regulation of hepcidin, which thereby controls iron absorption and
recycling in a manner that represents the net output of multiple inte-
grated signals.19 Population level associations between hepcidin and
iron stores and inﬂammation have likewise been demonstrated in
developed contexts.20 As the direct mediator of iron absorption and
recycling, hepcidin provides direct insight into iron physiology, particu-
larly utilization of oral iron. Hepcidin can be used to predict iron uptake
and utilization,21,22 as well as to distinguish iron deﬁcient children
within a population with a high burden of anemia and mixed iron deﬁ-
ciency and inﬂammation/infection.13
Several studies have previously evaluated the performance of hep-
cidin as an index of iron deﬁciency, in both population and clinical con-
texts, and interestingly, performance and optimal thresholds for
hepcidin to detect iron deﬁciency appear similar across diﬀerent popu-
lations and study designs, indicating biologic suppression of hepcidin in
iron deﬁciency.13,23 Multiple commercial hepcidin assays exist and the
absolute measurements they provide correlate well between assays,
however the diﬀerent assay systems are not directly comparable with-
out harmonization.5 Choi et al (n559) reported an AUCROC50.85 for
hepcidin to detect iron deﬁciency in Korean children aged 5 months to
17 years; a cutoﬀ of 6.895 ng/mL (using the Bachem assay) had a
sensitivity of 79.2% and speciﬁcity of 82.8%.23 In pre-selected Egyp-
tian children (n5100), urinary hepcidin had an AUCROC of 0.84, 0.94,
and 1.00 to detect mild and moderate ID, and IDA, respectively.24 In
FIGURE 2 ROC curves for hepcidin to identify iron deﬁciency. A, Hepcidin compared to ferritin<15 ng/mL, or <30 ng/mL if CRP>5 mg/
L, and sTfR-F index>2 (AUCROC 0.78) (n52203) B, using ferritin<15 ng/mL as the gold standard, comparing hepcidin (AUCROC 0.75) to
sTfR (AUCROC 0.66, P<0.001) and Hb (AUCROC 0.68, P<0.001) (n52149) C, ROC curve comparing the performance of hepcidin at distin-
guishing iron deﬁciency in samples without a- or b-thalassemia trait (AUCROC 0.79, n51620) with samples with a- (AUCROC 0.77, n5468)
and with b-thalassemia trait (AUCROC 0.75, n5101) (not signiﬁcant between any group). D, Youden indices [(sensitivity1 speciﬁcity)21] at
each cutoﬀ of hepcidin. (Inset) Youden indices in the range of 1.8–4.5 ng/mL. The maximal Youden index was 0.463 and occurred at a hep-
cidin cutoﬀ of 3.24 ng/mL (sensitivity, 76.8%; speciﬁcity, 69.6%). ROC5Receiver Operating Characteristic; AUC5Area Under Curve. [Color
ﬁgure can be viewed at wileyonlinelibrary.com]
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Australia, non-anemic female blood donors had an AUCROC of 0.89 to
detect iron deﬁciency (n5261).25 Wolﬀ et al studied healthy adult vol-
unteers (n533) and found that plasma and urine hepcidin had an
AUCROC to detect iron deﬁciency (deﬁned as ferritin<30 lg/L) of 0.94
and 0.93, respectively.26 Jonker et al compared hepcidin with bone
marrow iron stores in 87 non-inﬂamed Malawian children undergoing
elective surgery, and found that ferritin and sTfR outperformed hepci-
din as an index of iron deﬁciency, although hepcidin was still a poten-
tially useful biomarker. Utilizing similar gold standard deﬁnitions of iron
deﬁciency, we studied 1313 Gambian and Tanzanian pre-school chil-
dren, and observed that the AUCROC for hepcidin to identify iron deﬁ-
ciency was 0.85, with a threshold using the Bachem ELISA of 5.5 ng/
mL to distinguish iron deﬁciency across the overall population and
among anemic children.8,23 Current work is in progress to harmonize
hepcidin measurements across the range of diﬀerent kits and platforms
presently available.16 A threshold commutable to the value identiﬁed in
this study is therefore likely to be an appropriate candidate for diagno-
sis of iron deﬁciency.
Compared with studies in Africa, we found a lower AUCROC for
hepcidin to diagnose iron deﬁciency in this study. Unlike the African
population, anemia, and inﬂammation were uncommon in this study; as
such, distinction in hepcidin between cases with iron deﬁciency (which
produces hepcidin suppression) and cases with inﬂammation and iron
loading (with elevations in hepcidin) may have been less discrete. The
prevalence of iron deﬁciency based on our deﬁnition was relatively low
in this study; this is reﬂected here by low positive predictive value for
low hepcidin levels, which is typically the case when evaluating tests in
populations where the disease of interest is uncommon. Hepcidin was
a more accurate diagnostic test for iron deﬁciency than hemoglobin, as
we also observed in Africa. This reﬂects an emerging realization that in
the public health, anemia, and iron deﬁciency are not synonymous, and
often only a minority of cases of anemia are attributable to iron deﬁ-
ciency1; the corollary is that many cases of iron deﬁciency exist with-
out overt anemia. These data indicate that hemoglobin concentration
should not be used alone to identify iron deﬁciency.
Carriers of thalassemia have mildly increased erythropoiesis
(reﬂected by elevations in sTfR without low ferritin) due to modest
ineﬀective erythropoiesis with an imbalance of globin chains. Eleva-
tions in erythropoiesis and mild anemia likely cause an increase in the
expression of the bone marrow-derived hormone erythroferrone,
which acts to suppress expression of hepcidin.10 This represents a
milder phenotype to the condition seen in homozygote or compound
heterozygote thalassemia conditions.27 We were concerned that sup-
pression of hepcidin in patients carrying thalassemia could impair its
utility to detect iron deﬁciency in the same population. This distinction
is important as carriers of thalassemia may have increased iron absorp-
tion due hepcidin suppression. Reassuringly, our data indicated that the
AUCROC for hepcidin to detect iron deﬁciency was not diﬀerent
between thalassemia carriers and controls, and the optimal hepcidin
threshold was similar in carriers and non-carriers. Furthermore, unlike
hemoglobin, hepcidin measurement can help direct iron away from
iron-replete thalassemia carriers for whom iron supplementation may
be harmful.
Guided by the Youden index, a hepcidin cutoﬀ of 3.2 ng/mL had
the highest simultaneous speciﬁcity and sensitivity. However, this
threshold represents a tradeoﬀ between sensitivity and speciﬁcity and
selection of the appropriate cutoﬀ ultimately depends on the clinical or
public health scenario towhich it will be applied, based on the risk ofmis-
classifying an iron replete individual as iron deﬁcient or vice versa. In this
study, our reference (gold standard) was a combination of ferritin and
soluble transferrin receptor. These assays reﬂect bone marrow iron
stores and tissue iron need. Although thresholds used to deﬁne iron deﬁ-
ciency with these indices remain unclear and subject to ongoing re-con-
sideration,28 it would not have been feasible to measure bone marrow
iron in this large cross-sectional population study. The deﬁnitions of iron
deﬁciency we used here are widely accepted and have been previously
deployed in studies evaluating hepcidin as a diagnostic test.
In Sri Lankan adolescent children, the prevalence of anemia was
below the threshold for which a routine universal iron intervention pro-
gramme (for example daily or weekly iron supplementation) would be
considered. Indeed, because this study was enriched with patients
likely to carry hemoglobinopathies, the population prevalence of ane-
mia and iron deﬁciency in Sri Lanka is even lower still. Importantly, as
anemia is a poor index of iron status, it is also a poor guide for appro-
priate allocation of iron interventions in this setting. Strategies for opti-
mally directing iron interventions should ensure iron is preferentially
distributed to individuals that need it but not to those who are iron
replete (or infected) and who would not beneﬁt, or indeed in whom it
might be harmful. For this reason, we are currently prospectively evalu-
ating this approach in Gambian children29 and pregnant women.30
These trials together with the present diagnostic test accuracy study
may help develop the role of hepcidin to classify individuals “ready to
receive iron” for optimal stratiﬁcation in iron distribution programs.
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